0.88
price up icon0.65%   0.0057
pre-market  Vorhandelsmarkt:  .87   -0.01   -1.14%
loading
Schlusskurs vom Vortag:
$0.8743
Offen:
$0.88
24-Stunden-Volumen:
95,239
Relative Volume:
0.04
Marktkapitalisierung:
$11.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.41%
1M Leistung:
-7.47%
6M Leistung:
-88.59%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$0.85
$0.90
1-Wochen-Bereich:
Value
$0.831
$0.939
52-Wochen-Spanne:
Value
$0.69
$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Name
Firmenname
Scienture Holdings Inc
Name
Telefon
(800) 261 0281
Name
Adresse
2420 BRUNELLO TRACE, LUTZ
Name
Mitarbeiter
19
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
SCNX's Discussions on Twitter

Vergleichen Sie SCNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Pharmaceutical Retailers icon
SCNX
Scienture Holdings Inc
0.88 11.67M 0 0 0 0.00
Pharmaceutical Retailers icon
WBA
Walgreens Boots Alliance Inc
11.20 9.69B 151.95B -5.78B 571.00M -6.69
Pharmaceutical Retailers icon
HITI
High Tide Inc
2.29 184.54M 376.07M -22.41M 18.73M -0.298
Pharmaceutical Retailers icon
WGRX
Wellgistics Health Inc
1.88 179.65M 0 0 0 0.00
Pharmaceutical Retailers icon
PETS
Petmed Express Inc
3.82 77.87M 270.52M -6.08M 17.42M -0.2944
Pharmaceutical Retailers icon
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd
1.85 13.20M 0 0 0 0.00

Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten

pulisher
May 23, 2025

Scienture appoints Hariharan, Mani as co-CEOs - MSN

May 23, 2025
pulisher
May 22, 2025

SCIENTURE Appoint Dr. Shankar Hariharan and Dr. Narasimhan Mani as Co-CEO’s - citybiz

May 22, 2025
pulisher
May 22, 2025

Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

SCIENTURE Announces Executive Leadership Transition | SCNX Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

SCIENTURE Announces Executive Leadership Transition - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Scienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and Chairman - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Scienture Names Two Pharma Veterans as Co-CEOs in Strategic Leadership Overhaul - Stock Titan

May 22, 2025
pulisher
May 19, 2025

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Scienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan Formulation - Nasdaq

May 19, 2025
pulisher
May 19, 2025

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - The Manila Times

May 19, 2025
pulisher
May 19, 2025

FDA Orange Book Milestone: First-Ever Liquid Losartan Secures Patent Protection Until 2041 - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Long-Term Bull Put Spread Provides Opportunities for ARM Bulls - The Globe and Mail

May 19, 2025
pulisher
May 14, 2025

ON Holding Surges, Leads High-End Retailers Into Reversal - The Globe and Mail

May 14, 2025
pulisher
May 12, 2025

Scienture Holdings: Q1 Earnings Snapshot - CTPost

May 12, 2025
pulisher
May 12, 2025

Scienture Holdings, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 07, 2025

Why Rigetti Computing Stock Soared in April - The Globe and Mail

May 07, 2025
pulisher
May 01, 2025

3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail

May 01, 2025
pulisher
Apr 22, 2025

Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com

Apr 22, 2025
pulisher
Apr 22, 2025

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times

Apr 22, 2025
pulisher
Apr 22, 2025

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan

Apr 22, 2025
pulisher
Apr 11, 2025

Scienture Holdings Divests Subsidiaries to Tollo Health - MSN

Apr 11, 2025
pulisher
Apr 08, 2025

Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Scienture Holdings divests subsidiaries for $5 million - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times

Apr 08, 2025
pulisher
Apr 08, 2025

Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan

Apr 08, 2025
pulisher
Apr 05, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com

Apr 04, 2025
pulisher
Apr 04, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

Major Pharma Transformation: Scienture Reveals Two FDA-Approved Drugs and $480M+ Market Opportunity - Stock Titan

Apr 03, 2025
pulisher
Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025
pulisher
Mar 26, 2025

Scienture Holdings Inc. (SCNX) reports earnings - Quartz

Mar 26, 2025
pulisher
Mar 25, 2025

Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest

Mar 25, 2025
pulisher
Mar 25, 2025

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail

Mar 25, 2025
pulisher
Mar 21, 2025

Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Scienture Holdings Inc’s (NASDAQ:SCNX) Stock Price Plummets -72.07% This Year: A Look At Likely Future Paths - Stocksregister

Mar 21, 2025
pulisher
Mar 20, 2025

Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail

Mar 20, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Scienture Holdings announces draw on Equity Line of Credit - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Scienture announces draaw on Equity Line of Credit - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times

Mar 19, 2025

Finanzdaten der Scienture Holdings Inc-Aktie (SCNX)

Es liegen keine Finanzdaten für Scienture Holdings Inc (SCNX) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
pharmaceutical_retailers SSY
$0.873
price down icon 0.11%
$1.85
price up icon 58.12%
$24.34
price down icon 0.65%
$3.82
price up icon 3.24%
$1.88
price down icon 6.47%
Kapitalisierung:     |  Volumen (24h):